AngioConsult and Next-Biomed join forces to bring medical devices from concept to market
Speyer/Turin – November 3, 2026:
AngioConsult and Next-Biomed have entered a partnership to close the gap between device development and clinical studies. Going forward, both will jointly support start-ups and MedTech companies along the entire path of a medical device: from design and prototyping through first-in-human studies to market entry.
One partnership, fewer handovers
Bringing a minimally invasive medical device to market takes more than a good idea. Engineering, regulatory strategy, clinical evidence and a commercialization plan all have to fit together. In practice, companies often coordinate several service providers to cover these steps, and every handover costs time and knowledge.
The partnership between AngioConsult and Next-Biomed closes these gaps. Clients work with two specialized teams that coordinate closely and share one goal: getting safe and effective devices to patients faster.
Complementary expertise
Next-Biomed covers device development, engineering and prototyping, from early feasibility to prototypes that include biological tissue, as well as preclinical planning and verification and validation testing, up to first-in-human readiness. The team has worked on high-risk implantables, including heart valves and their delivery systems.
AngioConsult brings cardiovascular devices from the first-in-human study to market. It combines clinical study management and market access with hands-on case support on site. Its network of investigational sites, investigators and key opinion leaders (KOLs) connects clients with the right people early on.
What clients gain
Together, the partners cover the full path from concept to market. Where clients choose, projects can move seamlessly from Next-Biomed’s engineering team to AngioConsult’s clinical team, with preclinical and clinical planning aligned from the start. Clients benefit from consistent planning, fewer interfaces and a clear route from prototype to patient.
“Our clients want one thing above all: to reach patients safely and efficiently. Yet many promising devices lose valuable time on the way from development into the clinic. Together with Next-Biomed, we can now get involved from the very first design decision, so the clinical phase can start without delay.” says Benjamin Rieck, CEO of AngioConsult.
Enrico Pasquino, CEO of Next-Biomed, adds: “We’re pleased to build this partnership and bring complementary expertise together to better support medical device innovators throughout their development journey. By combining our perspectives and experience, we aim to help companies navigate technical, clinical and regulatory challenges in a more integrated and effective way.”
ABOUT THE COMPANIES
About AngioConsult:
AngioConsult GmbH, based in Speyer, Germany, supports medical device companies in the cardiovascular sector worldwide, from clinical development to commercialization. Its core strength is the combination of strategic advice and operational support on site. Service areas include Clinical Affairs, Regulatory & Notified Body Management, Quality Management and Market Access.
www.angioconsult.de
About Next-Biomed:
Next-Biomed is an engineering and advisory firm for medical devices, founded in Turin in 2025 and based in Leinì. It helps start-ups, SMEs and investors take medical devices from concept to certification and market, with engineering, preclinical and regulatory expertise in the same team.
www.next-biomed.com
